Priyanka
Analyst
J.P. Morgan
Equibles does not estimate personal net worth.
About Priyanka
Priyanka is recorded as Analyst at J.P. Morgan. Priyanka has spoken on 1 earnings call and 2 other investor events across 3 companies, most recently for Arcus Biosciences, Inc. on October 20, 2026. Those appearances were for Arcus Biosciences, Inc. (RCUS), Travere Therapeutics, Inc. (TVTX) and Ultragenyx Pharmaceutical Inc. (RARE). The companies whose calls Priyanka spoke on are classified in the Healthcare sector.
Priyanka on recent calls
“So it was mentioned that in Frontline there was no overlapping talks with the Zim-IPI combo.”
“Just a question on the sales team that's in place. I understand that there will be a proportion that will need to focus on pediatric nephrologists. I was just curious, how much larger would you consider growing the broader sales team to help cover that physician population?”
“Can we get more color on how ultrogenics is planning to achieve profitability in 2027 when burned in 2025? was around $466 million, and can you remind us how many drug launches will contribute to the”
Affiliation history
-
J.P. Morgan
Analyst
Transcript header (unverified)
Current